絞り込み

16638

広告

Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial.

著者 Misiukiewicz K , Gupta V , Miles BA , Bakst R , Genden E , Selkridge I , Surgeon JT , Rainey H , Camille N , Roy E , Zhang D , Ye F , Jia R , Moshier E , Bonomi M , Hwang M , Som P , Posner MR
Oral Oncol.2019 Aug ; 95():170-177.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (2view , 0users)

Full Text Sources

Miscellaneous

Human Papillomavirus oropharyngeal carcinoma (HPVOPC) has better progression free (PFS) and overall survival (OS) than non-HPVOPC. Standard-dose chemoradiotherapy (sdCRT) results in significant acute toxicity and late morbidity. We hypothesized that after induction chemotherapy (IC), reduced dose chemoradiation (rdCRT) would result in equivalent PFS and OS compared to sdCRT plus IC in HPVOPC and would reduce toxicity.
PMID: 31345387 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード